Allergen immunotherapy is the repeated administration of a substance responsible for an allergic reaction, in controlled amounts, to reduce sensitivity to subsequent exposure. Unlike treatments that mainly suppress symptoms, it acts on the allergen-specific immune response and can produce benefits that persist after treatment ends. Its principal established applications are pollen- and house-dust-mite–related allergic rhinitis, selected cases of allergic asthma, and systemic allergy to stinging-insect venom. Oral immunotherapy also raises reaction thresholds in selected people with food allergy, although protection often depends on continued dosing.
The treatment is not a single interchangeable procedure. Injected extracts, sublingual tablets, sublingual drops, and oral food preparations differ in composition, evidence, safety, and regulatory status. Their shared objective is to modify how the immune system responds to a particular allergen, rather than to suppress immune function generally. Clinical benefit depends on identifying the relevant allergen, selecting an effective preparation, and maintaining an appropriate treatment course.
Historical development and scope
Modern allergen immunotherapy developed from early attempts to treat hay fever by injecting pollen extracts. In 1911, Leonard Noon published work on prophylactic inoculation against hay fever; John Freeman subsequently extended this approach. Their work preceded the identification of the major molecular pathways of allergy. The original rationale emphasized protection against presumed pollen “toxins,” rather than the antibody-mediated mechanisms recognized today. Nevertheless, the practice established the central principle of giving increasing amounts of the material responsible for symptoms.
Over subsequent decades, treatment expanded from seasonal pollens to house-dust mites, animal allergens, molds, and insect venoms. Early preparations varied substantially in their biological potency and composition. Controlled studies, particularly from the mid-twentieth century onward, helped distinguish specific therapeutic effects from seasonal variation, changes in exposure, and the placebo effect. The discovery of immunoglobulin E in 1966–1967 supplied a molecular framework for understanding immediate allergic reactions and interpreting treatment-induced changes.
Subcutaneous injection became the dominant route for respiratory allergy and venom allergy. Sublingual administration developed as an alternative that placed allergen in contact with the oral mucosa. It gained a stronger evidence base through trials of defined tablets containing grass-pollen, ragweed-pollen, and house-dust-mite allergens. Sublingual liquid extracts are also used in some countries, but preparations and authorized indications vary. Evidence for a particular tablet or extract does not automatically establish efficacy for every product containing the same allergen source.
The term desensitization has several meanings in clinical medicine. In food immunotherapy, it usually denotes an increased reaction threshold maintained during regular treatment. In drug allergy, temporary desensitization can allow administration of an otherwise necessary medicine, but tolerance commonly disappears after dosing stops. That procedure is distinct from the prolonged courses of respiratory or venom immunotherapy intended to produce durable changes in allergic responsiveness.
Allergen immunotherapy is also distinct from treatment with a monoclonal antibody that blocks an allergic pathway. For example, an anti-IgE antibody reduces the availability of IgE to activate effector cells but does not itself administer a causative allergen. Such medicines may be used alongside immunotherapy or for separate allergic indications. Likewise, immunotherapy is not a general treatment for every condition described as an allergy: established respiratory protocols do not apply to nonallergic rhinitis, food intolerance, or most forms of allergic contact dermatitis.
Immunological mechanisms
Immediate allergic reactions commonly begin when an allergen binds to specific antibodies of the IgE class attached to high-affinity receptors on mast cells and basophils. Cross-linking of adjacent receptor-bound IgE molecules triggers the release of histamine, lipid mediators, and other substances. These produce itching, sneezing, mucus secretion, airway narrowing, vascular leakage, and, in severe reactions, anaphylaxis. Later recruitment of inflammatory cells can prolong symptoms beyond the initial exposure.
Allergen immunotherapy changes several parts of this response rather than operating through one universal switch. During successful treatment, mast cells and basophils become less readily activated by the relevant allergen. Allergen-specific IgE may initially rise, especially early in treatment, and may decline only gradually afterward. Clinical improvement can therefore occur without an early reduction in measured IgE. The concentration of IgE alone is not an adequate measure of therapeutic success.
Changes in T-cell regulation are central to longer-term effects. Allergic responses are often associated with type 2 helper T-cell activity and signaling molecules such as interleukins 4, 5, and 13. Immunotherapy can favor regulatory pathways that restrain these responses. Regulatory T cells and other regulatory cell populations contribute through mediators including interleukin-10 and transforming growth factor beta. The resulting effects include reduced inflammatory-cell recruitment and altered communication between antigen-presenting cells, T cells, and antibody-producing cells.
Treatment also commonly increases allergen-specific IgG, particularly IgG4. These antibodies can compete with IgE for allergen binding and reduce the amount of allergen available to activate effector cells. They can also interfere with IgE-facilitated allergen presentation to T cells. This “blocking antibody” activity helps explain why antibody function can be more informative than antibody concentration. A high IgG4 concentration, however, does not by itself establish that an individual is clinically protected.
The route of administration influences how allergen encounters immune cells. Injected allergens are taken up in tissue, while sublingual preparations interact with antigen-presenting cells in the oral mucosa. Food immunotherapy involves additional exposure through the gastrointestinal tract. These routes share regulatory mechanisms but differ in dose, absorption, local reactions, and the durability of their effects.
Three outcomes require distinction. Desensitization means reduced reactivity during ongoing exposure or treatment. Sustained unresponsiveness, increasingly called remission in food-allergy research, means that a defined degree of protection remains after treatment has been withheld for a specified interval. Tolerance implies a more stable state of nonreactivity. Because studies use different withdrawal periods and challenge procedures, apparent tolerance cannot be assumed to be permanent.
Establishing the indication and identifying the allergen
The basis for treatment is a clinically relevant allergic disease, not simply a positive laboratory result. Sensitization means that allergen-specific IgE is detectable or that a skin-prick test produces a response. Some sensitized individuals have no symptoms when exposed. Conversely, symptoms resembling allergy may arise from infection, irritants, structural disease, or nonallergic inflammation. The connection between exposure and illness is therefore established through medical history, examination, and appropriately interpreted testing.
For respiratory allergy, the timing and setting of symptoms help identify relevant exposures. Seasonal symptoms may correspond to local tree, grass, or weed pollen seasons; persistent indoor symptoms may relate to house-dust mites or animals. Regional pollen patterns matter because botanical sources differ geographically. A positive test to several pollens can reflect several genuine sensitizations, cross-reactive proteins shared by different plants, or a combination of both. Treating every positive result can produce unnecessarily complex mixtures without improving clinical relevance.
Component-resolved diagnostics measures IgE to individual allergenic molecules rather than only to whole extracts. In selected circumstances, it helps distinguish primary sensitization from cross-reactivity. For example, IgE to certain major pollen proteins supports sensitization to the corresponding source, while reactivity to widely shared proteins such as profilins can explain multiple positive extract tests. Component testing can also clarify some cases of bee and wasp venom sensitization. It supplements, rather than replaces, the clinical history.
Respiratory immunotherapy is generally studied in people with clinically significant allergic rhinoconjunctivitis, with or without selected forms of allergic asthma. Trials usually evaluate its effect in addition to permitted symptom-relieving treatment. Its relevance is especially clear when a specific exposure contributes substantially to disease burden. Evidence is less consistent for some animal and mold allergens than for well-studied pollen and mite preparations. The number of positive tests is not itself a measure of suitability.
Assessment of coexisting asthma is particularly important because poorly controlled asthma increases the consequences of a systemic allergic reaction. Symptoms, recent exacerbations, treatment requirements, and lung function assessed by spirometry contribute to risk characterization. Severe uncontrolled asthma is a major contraindication to starting or administering conventional allergen immunotherapy.
For venom allergy, the nature of the previous sting reaction is central. A large local swelling is different from a systemic reaction involving breathing, circulation, or multiple organ systems. Baseline serum tryptase and evaluation for mast-cell disease can identify additional risk in selected patients. For food allergy, supervised oral food challenges may establish the reaction threshold or clarify the diagnosis, but they carry their own risk and are not interchangeable with routine blood testing.
Respiratory immunotherapy: preparations and administration
Subcutaneous immunotherapy, often abbreviated SCIT, delivers allergen extract by injection beneath the skin. A conventional course has an initial build-up phase, during which the dose increases over repeated visits, followed by maintenance injections. Build-up commonly takes several months; maintenance injections are often separated by approximately four weeks, although schedules depend on the preparation and protocol. Treatment for respiratory allergy usually lasts three to five years when a sustained disease-modifying effect is intended.
Accelerated schedules compress the build-up period. Cluster schedules administer more than one injection at selected visits, while rush schedules reach a target dose over a much shorter interval. These approaches alter convenience and risk and may involve additional precautions or pretreatment. They are not equivalent simply because they eventually reach the same nominal maintenance dose. The allergen preparation, interval between doses, and patient’s clinical state all influence reactions.
Sublingual immunotherapy, or SLIT, places allergen beneath the tongue, usually as a dissolving tablet or liquid preparation. Licensed tablets generally use a fixed daily dose after an initial supervised administration, with subsequent treatment taken outside the clinic. Pollen regimens may be continuous or begin before the expected season and continue through it, depending on the product. House-dust-mite treatment is generally continuous. Exact age ranges, duration, and precautions are product- and jurisdiction-specific.
Allergen extracts are biological products. They contain mixtures of proteins whose abundance depends on source materials and manufacturing. Potency can be expressed using biological units or the quantity of particular major allergens, but units used by different manufacturers or regulatory systems are not necessarily interchangeable. Modified extracts, sometimes called allergoids, are chemically treated to reduce IgE-binding activity while retaining relevant immune-stimulating properties. Some injected preparations use adsorbing materials such as aluminum hydroxide to modify delivery.
Mixing allergens introduces additional technical considerations. Proteolytic enzymes in certain extracts, particularly some mold and insect preparations, can degrade proteins in other extracts. Combining many allergens also risks diluting each component below the dose supported by clinical evidence. A formulation’s compatibility and effective content therefore matter independently of the number of substances listed on its label.
Adherence is a major determinant of real-world effectiveness. Repeated clinic visits create a practical burden for injected treatment, while daily self-administered treatment requires persistence over years. Interruptions may lead to dose adjustments or renewed assessment under established protocols. Outcomes reported in closely monitored trials can exceed those achieved when treatment is discontinued early. The availability of a convenient route does not remove the need for prolonged treatment or establish that all routes are equally effective for every allergen.
Evidence for respiratory benefit and disease modification
Randomized trials and systematic reviews support the efficacy of selected subcutaneous and sublingual products for allergic rhinoconjunctivitis. Outcomes usually combine nasal and eye symptom scores with the amount of rescue medication used. This is important because lower symptom scores can otherwise reflect greater use of antihistamines or intranasal corticosteroids rather than a specific effect of immunotherapy. Changes in sleep, daily activities, and disease-specific quality of life provide complementary measures.
The size of benefit varies by allergen, product, dose, adherence, and natural exposure. Pollen seasons differ markedly between years and locations, complicating comparisons across studies. A trial conducted during a weak pollen season may have less ability to demonstrate an effect than one with substantial exposure. Environmental challenge chambers provide controlled exposure conditions, but their results do not fully reproduce everyday environments. Direct comparisons between injection and sublingual treatment are limited relative to the number of placebo-controlled studies of each route.
Persistence after discontinuation is a defining attraction of respiratory immunotherapy. Controlled grass-pollen studies have shown that benefit can remain for several years after an effective three-year course. This supports disease modification rather than only temporary symptom suppression. Duration matters: shorter courses have not consistently produced the same sustained effects. These findings cannot be generalized to every allergen, extract, or treatment schedule.
In allergic asthma, immunotherapy can reduce symptoms or medication requirements in selected populations, but the evidence is heterogeneous. Studies differ in disease severity, allergens, background treatment, and outcome definitions. A 2016 randomized controlled trial involving 834 adults with house-dust-mite–related asthma found that a mite sublingual tablet reduced the risk of moderate or severe exacerbation during a protocol-directed reduction in inhaled corticosteroid treatment. This design demonstrated an effect under specified conditions; it did not establish that immunotherapy replaces standard asthma treatment across all disease severities.
Whether respiratory immunotherapy prevents later asthma is a separate question. Earlier studies suggested preventive effects, but some had methodological limitations. The grass-pollen asthma prevention, or GAP, trial enrolled 812 children with grass-pollen allergic rhinoconjunctivitis and followed them through three years of treatment and two additional years. It did not meet its primary endpoint of preventing asthma onset under the trial’s specified definition. It did show reductions in asthma symptoms or asthma-medication use and sustained effects on rhinoconjunctivitis.
Claims that immunotherapy prevents new sensitizations also require caution. Findings vary by population, study design, and follow-up. Reduced test sensitization, reduced symptoms, and prevention of a newly diagnosed disease are different outcomes. The most secure evidence concerns improvement in established allergic respiratory disease and, for selected products and treatment durations, persistence of that improvement after treatment ends.
Venom immunotherapy
Venom immunotherapy treats systemic allergy to the venoms of stinging insects, particularly honeybees and vespid wasps such as yellow jackets. Related approaches use appropriate preparations for other insects in particular regions. Imported fire-ant immunotherapy, for example, commonly uses whole-body extracts rather than purified venom. The therapeutic aim is protection against future stings, which may otherwise provoke rapid and potentially life-threatening reactions.
The evidence for protection is strong. During maintenance treatment, venom immunotherapy prevents systemic reactions to subsequent stings in approximately 90–95% of patients with vespid allergy and roughly 80–85% with honeybee allergy, although estimates vary among studies. Honeybee treatment is generally associated with more treatment reactions and somewhat lower protection than vespid treatment. Differences in venom composition, allergen content, and exposure patterns contribute to this distinction.
A common maintenance dose is 100 micrograms of the relevant venom. Higher maintenance doses are used in selected circumstances, including systemic reactions despite a standard maintenance dose. Conventional, cluster, rush, and ultrarush schedules are used to reach maintenance. Accelerated schedules are particularly well established in venom treatment, where a high need for protection may coexist with frequent occupational or environmental exposure.
Treatment generally continues for three to five years, but duration is individualized according to recurrence risk. Factors associated with greater concern include very severe initial reactions, systemic reactions during treatment, honeybee allergy, frequent unavoidable exposure, and an underlying mast-cell disorder. Some patients remain on prolonged or indefinite therapy. Protection often persists after treatment stops, but it is not absolute, and a minority of patients experience systemic reactions to later stings.
Mastocytosis and other clonal mast-cell disorders are especially relevant to severe sting reactions. These disorders can increase the number or alter the behavior of mast cells, and severe cardiovascular reactions may occur with relatively few skin manifestations. An elevated baseline tryptase can be a clue, although it is not specific to mastocytosis. Recognizing this association influences the interpretation of the reaction and the expected risk after treatment withdrawal.
Venom immunotherapy has benefits beyond preventing physiological reactions. Fear of an unpredictable sting can restrict outdoor activities and occupational participation. Clinical studies have documented improvements in disease-specific quality of life compared with approaches relying only on emergency medication. Nevertheless, treatment success cannot be inferred from falling venom-specific IgE alone. An accidental tolerated sting provides relevant information but is an uncontrolled exposure; supervised sting challenges are used in some specialist settings to assess protection.
Food allergen immunotherapy
Food immunotherapy differs from respiratory and venom treatment because the usual objective is to increase the amount of food that can be ingested before a reaction occurs. Oral immunotherapy, or OIT, uses measured amounts of the food allergen, commonly with an initial escalation phase, gradual dose increases, and regular maintenance. Peanut, milk, and egg have been studied extensively, but evidence and product availability differ by food and jurisdiction.
The principal demonstrated outcome is desensitization. A person who initially reacts to a small quantity may tolerate a substantially larger quantity during treatment. This can create a buffer against some accidental exposures, but it does not establish unrestricted tolerance. Missed doses, illness, exercise, fasting, and other cofactors can alter reaction risk. Maintenance dosing can itself cause allergic reactions, including reactions to amounts previously tolerated.
The PALISADE phase 3 trial, published in 2018, illustrates both efficacy and the need for precise outcome interpretation. Among participants aged 4–17 years, 67.2% receiving a standardized peanut oral immunotherapy product tolerated a challenge dose of at least 600 milligrams of peanut protein without dose-limiting symptoms, compared with 4.0% receiving placebo. This was a challenge-threshold endpoint after treatment, not proof of permanent resolution. The United States first approved that standardized peanut product in 2020 for a defined pediatric population.
Studies of younger children suggest that age and baseline allergic characteristics may influence the probability of remission. The IMPACT trial studied peanut oral immunotherapy in children aged one to three years. It demonstrated substantial desensitization during treatment, while a smaller proportion retained the specified protection after a period of peanut avoidance. Differences between on-treatment and post-withdrawal results illustrate why sustained unresponsiveness must be measured separately.
Adverse effects are an important limitation. Oral itching, abdominal symptoms, and systemic reactions can occur. Eosinophilic esophagitis, an immune-mediated inflammatory disease of the esophagus, has been diagnosed in a minority of patients receiving oral immunotherapy. Persistent swallowing difficulties, feeding problems, or gastrointestinal symptoms are therefore clinically significant in treatment studies and surveillance. The respective contributions of newly induced disease and previously unrecognized disease are not fully resolved in every case.
Other routes include sublingual food immunotherapy and epicutaneous immunotherapy, which delivers allergen through a skin patch. These generally use smaller allergen quantities and have different efficacy and adverse-effect profiles. They are not interchangeable with oral treatment. Studies also evaluate combining food immunotherapy with biologic medicines, particularly anti-IgE therapy, to improve tolerability or facilitate dose escalation. Anti-IgE treatment without allergen administration is a separate therapeutic strategy and should not be described as food allergen immunotherapy.
Adverse effects, contraindications, and treatment safety
Adverse effects depend strongly on route. Subcutaneous treatment commonly causes redness, itching, or swelling at the injection site. Larger local reactions can be uncomfortable but do not reliably predict whether the next injection will cause a systemic reaction. Systemic reactions range from generalized urticaria to respiratory compromise or circulatory collapse. Surveillance studies often report systemic reactions in the order of one per thousand injection visits, but rates vary with definitions, protocols, and populations. Fatal reactions are very rare but have occurred.
Because many serious injection reactions begin soon after administration, supervised post-injection observation is integral to treatment protocols. An observation period of at least 30 minutes is common, although delayed reactions are also recognized. Clinical services administering injections require procedures for identifying and treating anaphylaxis. Epinephrine is the first-line medicine for anaphylaxis; antihistamines do not reverse its respiratory or cardiovascular effects.
Sublingual treatment more often causes local oral or throat symptoms, especially early in the course. Itching, mild swelling, and irritation frequently diminish with continued treatment. Severe systemic reactions are much less frequent than with injections but are possible. Product instructions differ concerning supervised initiation, interruption during particular illnesses or oral conditions, and access to emergency medication. A history of eosinophilic esophagitis is a contraindication to several licensed sublingual tablet products.
Poorly controlled asthma is one of the most important modifiable risk factors for severe reactions. Other practical contributors include dosing errors, changes in extract potency, inadvertent intramuscular administration, and failure to account for a prolonged treatment interruption. High allergen exposure during a pollen season can also affect tolerability. Consequently, safety depends not only on patient selection but also on prescribing systems, preparation identification, documentation, and administration procedures.
Coexisting conditions and medicines can complicate risk assessment. Beta blockers may interfere with physiological responses involved in treating anaphylaxis, while cardiovascular disease can increase the consequences of a severe reaction. Their significance depends on the indication and clinical context; venom allergy, for example, may itself carry substantial risk. These situations are assessed through individualized benefit–risk evaluation rather than a single rule applicable to every patient.
Initiating immunotherapy during pregnancy is generally avoided because a systemic reaction could affect both the pregnant patient and fetus. Established maintenance treatment may be continued in selected circumstances under clinical supervision without dose escalation. Evidence for other populations, including people with active systemic disease or receiving substantial immunosuppression, is more limited and condition-specific. Precautions for one route or preparation cannot automatically be transferred to all other forms of immunotherapy.
Measuring outcomes and developing more precise treatment
Clinical assessment of immunotherapy centers on outcomes meaningful to the condition being treated. For rhinitis, these include symptoms, rescue medication use, sleep, daily functioning, and seasonal burden. For asthma, exacerbations, medication requirements, symptom control, and lung function are relevant. For venom allergy, the central outcome is protection against systemic reactions to subsequent stings. For food allergy, oral challenge thresholds, treatment-related reactions, and protection after withdrawal must be reported separately.
Research interpretation requires attention to trial design. A clinical trial that shows improvement over placebo does not necessarily establish superiority over another active treatment. Different symptom scales, rescue-medication rules, exposure levels, and treatment durations complicate cross-trial comparisons. Local reactions can sometimes reveal treatment allocation, potentially weakening blinding. Long-term studies also face selective dropout: people who discontinue because of inconvenience, adverse effects, or limited benefit may differ from those who remain.
No single validated routine biomarker reliably identifies every future responder or confirms that treatment can safely stop. Allergen-specific IgE, IgG4, skin-test responses, and basophil activation can change during therapy, but their relationship to individual clinical outcomes is imperfect. Research increasingly examines functional antibody assays, cellular profiles, and patterns of gene expression. A marker that correlates with improvement in a group still requires validation before it can guide decisions for individual patients.
Molecular approaches aim to make preparations more reproducible and less allergenic. Recombinant allergens, selected allergen fragments, and synthetic peptides can define the administered material more precisely than conventional extracts. Some designs reduce the capacity to cross-link IgE while preserving recognition by T cells. Others combine allergens with immune-modifying carrier proteins or adjuvants. Early biological activity is not sufficient to establish durable clinical benefit, and many approaches remain investigational.
Alternative delivery methods include direct injection into lymph nodes and application to disrupted or intact skin. Intralymphatic immunotherapy is intended to expose immune tissue efficiently with fewer administrations, but studies have produced variable results and have not established it as a general replacement for standard routes. For skin-based approaches, allergen dose delivery, local inflammation, and the relationship between barrier function and immune response remain important technical issues.
Health-service questions are equally consequential. Travel, repeated visits, daily dosing, product costs, and inconsistent reimbursement affect persistence and access. Economic analyses may find favorable long-term value when sustained benefit reduces later medication use and disease burden, but their conclusions depend on assumptions about adherence, duration of effect, and local costs. Treatment registries and pharmacovigilance complement trials by documenting uncommon adverse events, use in broader populations, and outcomes after treatment discontinuation.